Dr. Andrew Feigin, a leading neurologist, brings 30 years of experience to his position of Chief Medical Officer (CMO). In this global role, he provides medical strategy and operational expertise across multiple therapeutic areas and ensures the integrity and safety of clinical trials.

Dr. Feigin’s career is marked by groundbreaking contributions to neurology and clinical research. After completing a fellowship in experimental therapeutics, he joined North Shore University Hospital, where he established a renowned clinical trial program for patients with Parkinson’s disease, Huntington’s disease, Tourette syndrome, and other movement disorders. Prior to joining Rho, Dr. Feigin was a Professor of Neurology at NYU Langone Health where he directed the Marlene and Paolo Fresco Institute for Parkinson’s and Movement Disorders. His impressive track record includes serving as the site principal investigator on more than 30 clinical trials, notably spearheading the first phase 1 clinical trial using gene therapy for Parkinson’s disease. He has also served as the global principal investigator for several large multicenter clinical trials for Huntington’s disease.

Before joining Rho, Dr. Feigin led a team that founded a boutique CRO for a rare disease study group, an endeavor that reinforced his passion for impactful clinical research. His desire to amplify his impact on patient lives led him to Rho, where he sees immense potential for collaboration and innovation.

Dr. Feigin graduated from Columbia University Vagelos College of Physicians and Surgeons in 1988. He is a distinguished member of the American Academy of Neurology, the American Neurological Association, the Movement Disorder Society, the Parkinson Study Group, and the Huntington Study Group. His prolific contributions to the field include over 150 peer-reviewed articles and numerous advisory board positions.